Country lead and senior director
Alasdair Godfrey joined Optum as Asia Pacific leader in February of 2014. Since coming to Optum, he has been responsible for building the new Optum team of Health Economic and Outcomes Research specialists, and re-launching the Optum brand in the Australian medical industry environment and more generally in the APAC region. Alasdair has also had oversight (strategic and technical) on all ongoing projects including draft manuscripts, reimbursement submissions, feasibility studies, systematic reviews and clinical practice guidelines.
Prior to joining Optum, Alasdair has served in mixed medical industry roles including within the medical device industry in APAC, another large market access consultancy where he completed numerous reimbursement submissions and a set of internationally adopted clinical practice guidelines. As a market access and health policy expert, Alasdair has been selected as an evaluator in the past for the Australian Medical Services Advisory Committee (MSAC) and managed several complex evaluations for medical devices, co-dependent technology, diagnostic tests and clinical procedures. Before Optum, he had autonomous responsibility for Health Outcomes at a large global pharmaceutical company specialising mainly in injectable oncology products. The organisation was also a leader in the developing field of follow-on biological medicinal products (SBMPs or “Biosimilars”). Owing to this, Alasdair became involved in very early policy conversations with the Pharmaceutical Benefits Division (PBD) and Pharmaceutical Benefits Advisory Committee (PBAC) and was asked to participate in a variety of advisory groups and expert committees by the Australian Federal Government regarding appropriate patient access to, nomenclature for and reimbursement of SBMPs.
Alasdair has a medical and scientific academic background with degrees in medicine and genetics. Prior to moving to Australia in early 2000s, he held clinical, research and academic positions in the UK (Cambridge and Glasgow) mainly focused in the therapeutic areas of oncology and autoimmune diseases. His main interests are around co-dependent technologies (or personalised medicine), remote monitoring technology, the changing environment of global and regional health policy, government decision-making processes, the impact and issues of follow-on biological medicines and equitable access to best health care.